Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28559026 | 1.00 | SIGMAR1 (0.58) | SIGMAR1ALDH1A1LMNANR3C1KDM4E | |
| SCHEMBL14376971 | 0.81 | TSHR (0.53) | ALDH1A1LMNAKDM4EMEN1KMT2A | |
| SCHEMBL28217942 | 0.75 | SIGMAR1 (1.00) | SIGMAR1ALDH1A1LMNAKDM4EMEN1 | |
| SCHEMBL2961574 | 0.73 | SIGMAR1 (0.50) | SIGMAR1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL20149768 | 0.73 | SIGMAR1 (0.62) | SIGMAR1KMT2AHRH2 | |
| SCHEMBL7016275 | 0.71 | SIGMAR1 (0.72) | SIGMAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL14377687 | 0.71 | KDM4E (0.48) | ALDH1A1LMNAKDM4EMEN1KMT2A | |
| SCHEMBL7570843 | 0.70 | SIGMAR1 (0.53) | SIGMAR1LMNAKDM4EMEN1KMT2A | |
| SCHEMBL5190470 | 0.70 | GAA (0.47) | SIGMAR1ALDH1A1LMNAMEN1KMT2A | |
| SCHEMBL28566154 | 0.70 | CYP2D6 (0.43) | SIGMAR1ALDH1A1LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486280-B2 | CDK inhibitors and uses thereof | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2025-12-02 | — | — | US | disclosed |
| EP-3830082-B1 | CDK INHIBITORS AND USES THEREOF | CALIFORNIA INST OF TECHN (US) | 2025-02-26 | — | — | EP | disclosed |
| US-20220106325-A1 | CDK INHIBITORS AND USES THEREOF | 1200 PHARMA LLC | 2022-04-07 | — | — | US | disclosed |
| CN-112703186-A | CDK inhibitors and uses thereof | 加利福尼亚技术学院 | 2021-04-23 | — | — | CN | disclosed |
| WO-2020023917-A1 | CDK INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2020-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106325-A1 | CDK INHIBITORS AND USES THEREOF | CDK6, CDK4, CDK3 | SIGMAR1 4719/4885ALDH1A1 3716/4885LMNA 1954/4885 |
| US-12486280-B2 | CDK inhibitors and uses thereof | CDK6, CDK4, CDK3 | SIGMAR1 4719/4885ALDH1A1 3716/4885LMNA 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.